02151nas a2200229 4500008004100000245010200041210006900143260001500212300001200227490000700239520147800246653001901724653002901743653001501772653001601787653001401803653001101817100002101828700000501849700002701854856004001881 2024 eng d00aMozart K488 Addition Can Improve Depressive-Like Behavior in Rats: In Search of Better Management0 aMozart K488 Addition Can Improve DepressiveLike Behavior in Rats cApril 2024 a348-3540 v163 a

Background: Fluoxetine is one of the medications used for the treatment of depression with several benefits, but some patients have a poor response to the drug. Several studies reported the use of Mozart music (K448) as an alternative therapy for treating the condition, yet the combination of Mozart and fluoxetine remains underexplored. In light of this, this study aims to assess the impact of combined fluoxetine and Mozart (K448) therapy on depressive-like behavior and associated hormonal changes in a rodent model subjected to Chronic Unpredictable Mild Stress (CUMS) conditions. Materials and Methods: The depression-induced animal model received one of these three specified treatments: fluoxetine (F), Mozart (M), or a combination of fluoxetine and Mozart (F+M). The depressive-like behavior was assessed using a 24-hour sucrose preference test (SPT). Additionally, after 21 days of treatment, plasma corticosterone levels and hippocampal melatonin levels were assessed. Statistical analysis using either ANOVA or Kruskal-Wallis tests was then performed. Results: The fluoxetine-Mozart group had higher SPT compared to CUMS group. However, they do not have a better result compared to other groups in terms of corticosterone and melatonin levels with values of respectively. Conclusion: The combined therapy of fluoxetine and Mozart improved depressive-like behavior.

10aCorticosterone10aDepressive-like behavior10aFluoxetine10aHippocampus10aMelatonin10aMozart1 aPangemanan, Lisa1 a1 aMaramis, Margarita, M. uhttps://www.phcogj.com/article/2255